Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation

Vaccine

Volumn 29, Issue 48, 2011, Pages 9064-9074

  Kumar, Rajnish ^a   Tuen, Michael ^a,b   Li, Hualin ^a,c   Tse, Doris B ^a   Hioe, Catarina E ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibody response; HIV 1; HIV 1 envelope; Immune complex vaccine; N glycan

Indexed keywords

GLYCAN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; NEUTRALIZING ANTIBODY; QS 21; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS STRAIN; WILD TYPE;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; CELL PROLIFERATION; CYTOKINES; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTRALIZATION TESTS; POLYSACCHARIDES; T-LYMPHOCYTES;

EID: 82455192354     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.057     Document Type: Article

References (55)

1. Back N.K., Smit L., De Jong J.J., Keulen W., Schutten M., Goudsmit J., et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994, 199(March (2)):431-438.
2. McCaffrey R.A., Saunders C., Hensel M., Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004, 78(April (7)):3279-3295.
3. Reynard F., Fatmi A., Verrier B., Bedin F. HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology 2004, 324(June (1)):90-102.
4. Wu Z., Kayman S.C., Honnen W., Revesz K., Chen H., Vijh-Warrier S., et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol 1995, 69(April (4)):2271-2278.
5. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., et al. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 2010, 285(July (27)):20860-20869.
6. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5(March (3)):233-236.
7. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998, 4(June (6)):679-684.
8. Sugimoto C., Nakayama E.E., Shioda T., Villinger F., Ansari A.A., Yamamoto N., et al. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant. J Gen Virol 2008, 89(February (Pt 2)):554-566.
9. Sugimoto C., Watanabe S., Naruse T., Kajiwara E., Shiino T., Umano N., et al. Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. PLoS One 2010, 5(7):e11678.
10. Mori K., Sugimoto C., Ohgimoto S., Nakayama E.E., Shioda T., Kusagawa S., et al. Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model. J Virol 2005, 79(August (16)):10386-10396.
11. Bolmstedt A., Hinkula J., Rowcliffe E., Biller M., Wahren B., Olofsson S. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine 2001, 20(November (3-4)):397-405.
12. Bolmstedt A., Sjolander S., Hansen J.E., Akerblom L., Hemming A., Hu S.L., et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12(July (3)):213-220.
13. Quinones-Kochs M.I., Buonocore L., Rose J.K. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 2002, 76(May (9)):4199-4211.
14. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008, 82(January (2)):638-651.
15. Li H., Chien P.C., Tuen M., Visciano M.L., Cohen S., Blais S., et al. Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 2008, 180(March (6)):4011-4021.
16. Li H., Xu C.F., Blais S., Wan Q., Zhang H.T., Landry S.J., et al. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J Immunol 2009, 182(May (10)):6369-6378.
17. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 2006, 28(3):255-265.
18. Zolla-Pazner S., Cohen S., Pinter A., Krachmarov C., Wrin T., Wang S., et al. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009, 392(September (1)):82-93.
19. Vaine M., Wang S., Crooks E.T., Jiang P., Montefiori D.C., Binley J., et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008, 82(August (15)):7369-7378.
20. Wang S., Parker C., Taaffe J., Solorzano A., Garcia-Sastre A., Lu S., et al. DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008, 26(July (29-30)):3626-3633.
21. Hioe C.E., Visciano M.L., Kumar R., Liu J., Mack E.A., Simon R.E., et al. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 2009, 28(December (2)):352-360.
22. Visciano M.L., Tuen M., Gorny M.K., Hioe C.E. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 2008, 372(March (2)):409-420.
23. Visciano M.L., Tuen M., Chen P.D., Hioe C.E. Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect Agent Cancer 2008, 3:11.
24. Yu B., Fonseca D.P., O'Rourke S.M., Berman P.W. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J Virol 2010, 84(Februaly (3)):1513-1526.
25. Sjolander S., Bolmstedt A., Akerblom L., Horal P., Olofsson S., Morein B., et al. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Virology 1996, 215(January (2)):124-133.
26. Tuen M., Visciano M.L., Chien P.C., Cohen S., Chen P.D., Robinson J., et al. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur J Immunol 2005, 35(September (9)):2541-2551.
27. Chien P.C., Cohen S., Tuen M., Arthos J., Chen P.D., Patel S., et al. Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J Virol 2004, 78(July (14)):7645-7652.
28. Chapman H.A. Endosomal proteases in antigen presentation. Curr Opin Immunol 2006, 18(February (1)):78-84.
29. Hsing L.C., Rudensky A.Y. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 2005, 207(October):229-241.
30. Wolf P.R., Ploegh H.L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 1995, 11:267-306.
31. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4(September (5)):388-393.
32. Forthal D.N., Landucci G., Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75(August (15)):6953-6961.
33. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2007, 25(February (8)):1398-1408.
34. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997, 94(August (17)):9378-9383.
35. 4+ T cell-proliferative responses to glycoprotein 120. AIDS Res Hum Retroviruses 2000, 16(June (9)):893-905.
36. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(June (6686)):648-659.
37. Chien P.C., Cohen S., Kleeberger C., Giorgi J., Phair J., Zolla-Pazner S., et al. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis 2002, 186(July (2)):205-213.
38. Hioe C.E., Tuen M., Chien P.C., Jones G., Ratto-Kim S., Norris P.J., et al. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol 2001, 75(November (22)):10950-10957.
39. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(August (5993)):856-861.
40. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(August (5993)):811-817.
41. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445(February (7129)):732-737.
42. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(November (5187)):1024-1027.
43. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994, 68(December (12)):8312-8320.
44. Pinter A., Honnen W.J., D'Agostino P., Gorny M.K., Zolla-Pazner S., Kayman S.C. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005, 79(June (11)):6909-6917.
45. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70(March (3)):1863-1872.
46. Wen Y.M. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 2009, 9(March (3)):285-291.
47. Xu D.Z., Zhao K., Guo L.M., Li L.J., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008, 3(7):e2565.
48. Alber D.G., Killington R.A., Stokes A. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Vaccine 2000, 19(November (7-8)):895-901.
49. Ivan J., Velhner M., Ursu K., German P., Mato T., Dren C.N., et al. Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can J Vet Res 2005, 69(April (2)):135-142.
50. Roic B., Cajavec S., Ergotic N., Lipej Z., Madic J., Lojkic M., et al. Immune complex-based vaccine for pig protection against parvovirus. J Vet Med B: Infect Dis Vet Public Health 2006, 53(February (1)):17-23.
51. Getahun A., Heyman B. How antibodies act as natural adjuvants. Immunol Lett 2006, 104(April (1-2)):38-45.
52. Heyman B. The immune complex: possible ways of regulating the antibody response. Immunol Today 1990, 11(September (9)):310-313.
53. Song H., Nie X., Basu S., Cerny J. Antibody feedback and somatic mutation in B cells: regulation of mutation by immune complexes with IgG antibody. Immunol Rev 1998, 162(April):211-218.
54. Ratcliffe A., Stanworth D.R. The use of synthetic gamma-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages. Immunol Lett 1982, 4(April (4)):215-221.
55. Ratcliffe A., Stanworth D.R. The localization of the binding site(s) on human IgG1 for the Fc receptors on homologous monocytes and heterologous mouse macrophages. Immunology 1983, 50(September (1)):93-100.